Trial Profile

A randomized, double-blind, placebo-controlled Phase I study of single and multiple ascending doses of IMSB301 in healthy subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Oct 2024 According to an ImmuneSensor media release, status changed from not yet recruiting to recruiting.
08 Oct 2024 According to an ImmuneSensor media release, the first dose level cohort of healthy volunteers has been dosed in this study. and company anticipate having safety, pharmacokinetic, and target engagement data from our Phase 1 trial in healthy volunteers by the end of 2024.
19 Aug 2024 According to an ImmuneSensor media release, the company expects to initiate its Phase 1 clinical trial in healthy volunteers in 3Q2024 and move rapidly into Phase 1b/2 clinical studies in Type I interferonopathies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com